Intermountain Health, a Utah-based, not-for-profit system of 33 hospitals, health plans and a medical group, has launched a new biotechnology company, Culmination Bio.
The company will develop an exclusive, anonymized and de-identified intelligence platform that will aim to develop novel clinical insights, discoveries and care processes, according to Intermountain. The precision medicine play will work on a multi-modal intelligence platform that will give customers access to omics-level data and a powerful insights engine for medical research, health data and healthcare services. The aim of the biotech company is to “transform healthcare by providing comprehensive information on patient predisposition to disease, disease prevention and personalized intervention and treatments,” the company said.
“Culmination Bio was built to expand on the success of Intermountain’s precision medicine efforts by creating longitudinal multi-modal data sets,” Lincoln Nadauld, MD, PhD, CEO of Culmination, said in a statement. “Culmination’s powerful insights platform will unlock the next generation of discoveries to advance healthcare. Our focus is to discover better health for patients everywhere. Our partnership with Intermountain Health has enabled us to build a platform that will revolutionize the way we identify and implement novel clinical insights to benefit patients.”
The company was launched from Intermountain Ventures, the venture capital arm of Intermountain Health.
A core component of the Culmination Bio database is real-world data and evidence generation tied to the performance of diagnostics and therapeutics. The intelligence platform includes millions of data points, housing an environment for “sophisticated queries of data to identify new diagnostic tests and treatments that will result in better care for patients,” Intermountain said.
In addition to Nadauld being named president and CEO of Culmination Bio, Intermountain Health also announced several other key leadership appointments, including:
- Michael Wiley, JD, CPA, Chief Operating Officer
- Mark Oldroyd, JD, MS, Chief Commercial Officer
- McCall Rowley, Interim Chief Financial Officer
- Casey Frankenberger, PhD, Senior Vice President, Head of Data
- David Jones, PhD, Senior Vice President, Head of Science
- Harry Hayter, Senior Vice President, Strategic Partnerships
Part of the business plan includes commercial partners, such as technology and biopharmaceutical companies, healthcare institutions and the millions of patients treated by these organizations.
Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."